NEW YORK, Oct. 14, 2021 /PRNewswire/ --BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, will present findings from a multicenter, open label clinical trial of NurOwn in progressive multiple sclerosis. The study, "Phase 2 Safety and Efficacy Study of Intrathecal MSC-NTF cells in Progressive Multiple Sclerosis," will be delivered in an oral presentation today at the fully digital37thCongress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS).
The Phase 2 clinical trial was designed to evaluate intrathecal administration of NurOwn (autologous MSC-NTF cells) in participants with progressive MS. The study achieved the primary endpoint of safety and tolerability. It demonstrated a reduction of neuroinflammatory biomarkers and an increase in neuroprotective biomarkers in the cerebrospinal fluid (CSF) and consistent improvement across MS functional outcome measures, including measures of walking, upper extremity function, vision and cognition.
"We were pleased that this study demonstrated safety, preliminary evidence of efficacy and relevant biomarker outcomes in patients with progressive multiple sclerosis, in an area of high unmet need," said Jeffrey Cohen, M.D., Director of Experimental Therapeutics at the Cleveland Clinic Mellen Center for MS and principal investigator for the trial. "These results should be confirmed in a randomized placebo-controlled trial."
The study was sponsored by Brainstorm Cell Therapeutics with additional financial support for biomarker analyses from the National Multiple Sclerosis Society Fast-Forward Program. It was conducted at four U.S. MS centers of excellence:
"We very much appreciate the tremendous collaboration among many premier organizations, for their generous sharing of expertise, support and data, which enabled the important balance between scientific rigor and ethical treatment of progressive MS participants in the trial," said Ralph Kern, M.D., MHSc., President and Chief Medical Officer, Brainstorm Cell Therapeutics. "We are holding discussions with key MS experts, and seeking guidance from the FDA to determine next steps for the development of NurOwn in progressive MS."
"The National MS Society is pleased to support the biomarker portion of this study through our commercial funding program Fast Forward," said Mark Allegretta, Ph.D., Vice President, Research. "We're encouraged to see evidence that the biomarker analysis showed proof of concept for detecting neuroprotection and reduced inflammation."
About the trial
The Phase 2 open-label studyevaluated the safety and efficacy of intrathecal administration of autologous MSC-NTF cells in patients with primary or secondary progressive MS. The primary study endpoint was safety and tolerability. Secondary efficacy endpoints included: timed 25-foot walk (T25FW); 9-Hole Peg Test (9-HPT); Low Contrast Letter Acuity (LCLA); Symbol Digit Modalities Test (SDMT); 12 item MS Walking Scale (MSWS-12); as well as cerebrospinal fluid (CSF) and blood biomarkers. Clinical efficacy outcomes were compared with matched (n=48) participants in the Comprehensive Longitudinal Investigation of Multiple Sclerosis (CLIMB) registry, Tanuja Chitnis, MD Brigham and Women's Hospital and the Ann Romney Center for Neurologic Diseases, and 255 patient randomized double blind placebo controlled NN-102 SPRINT-MS Study, courtesy NIH/NINDS, PI: Robert J. Fox, MD, MS, FAAN, Cleveland Clinic, CTR: NCT01982942. Baseline characteristics from these two cohorts were similar allowing for comparison of efficacy results, comparisons with SPRINT-MS were with the placebo arm of this study.
Mean age of participants was 47 years, 56% were female, and mean baseline EDSS score was 5.4. 18 participants were treated, 16 (80%) received all 3 treatments and completed the entire study; 2 study discontinuations were due to procedure-related adverse events. No deaths or treatment-related adverse events due to worsening of MS were observed.
In responder analyses, 14% and 13% of MSC-NTF treated participants showed at least a 25% improvement in T25FW and 9-HPT (combined hands) respectively, compared to 5% and 0% in matched CLIMB patients and 9% and 3% in SPRINT. Twenty-seven percent (27%) showed at least an 8-letter improvement in LCLA (binocular, 2.5% threshold) and 67% showed at least a 3-point improvement in SDMT, compared to 6% and 18% in CLIMB and 13% and 35% in SPRINT, respectively.
Mean improvements of +0.10 ft/sec in T25FW and -0.23 sec in 9-HPT (combined hands), were observed in MSC-NTF treated participants, compared to a mean worsening of -0.07 ft/sec and +0.49 sec in CLIMB and -0.06 ft/sec and +0.28 sec in SPRINT, respectively. MSC-NTF treated participants showed a mean improvement of +3.3 letters in LCLA (binocular, 2.5% threshold) and 3.8 points in SDMT, compared to a mean worsening of -1.07 letters in LCLA (binocular, 2.5% threshold) and mean improvement of +0.10 in SDMT, in CLIMB and -0.6 and -0.1 in SPRINT. In addition the MSFC-4 Composite Z-score of T25W, 9-HPT, SDMT and LCLA showed a 0.18 point improvement in MSC-NTF treated participants, while CLIMB and SPRINT showed decreases of -0.02 and -0.05.
Furthermore, 38% of treated patients showed at least a 10-point improvement in the MSWS-12 a patient reported outcome that evaluates the impact of MS on walking function, whereas this outcome was not evaluated in CLIMB or SPRINT.
CSF biomarkers obtained at 3 consecutive time points, showed increases in neuroprotective molecules (VEGF, HGF, NCAM-1,Follistatin, Fetuin-A) and decreases in neuroinflammatory biomarkers (MCP-1, SDF-1, sCD27 and Osteopontin).
The NurOwntechnology platform (autologous MSC-NTF cells) represents a promising investigational therapeutic approach to targeting disease pathways important in neurodegenerative disorders. MSC-NTF cells are produced from autologous, bone marrow-derived mesenchymal stem cells (MSCs) that have been expanded and differentiated ex vivo. MSCs are converted into MSC-NTF cells by growing them under patented conditions that induce the cells to secrete high levels of neurotrophic factors (NTFs). Autologous MSC-NTF cells are designed to effectively deliver multiple NTFs and immunomodulatory cytokines directly to the site of damage to elicit a desired biological effect and ultimately slow or stabilize disease progression.
About BrainStorm Cell Therapeutics Inc.
BrainStorm Cell Therapeutics Inc. is a leading developer of innovative autologous adult stem cell therapeutics for debilitating neurodegenerative diseases. The Company holds the rights to clinical development and commercialization of the NurOwntechnology platform used to produce autologous MSC-NTF cells through an exclusive, worldwide licensing agreement. Autologous MSC-NTF cells have received Orphan Drug designation status from the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for the treatment of amyotrophic lateral sclerosis (ALS). BrainStorm has completed a Phase 3 pivotal trial in ALS (NCT03280056); this trial investigated the safety and efficacy of repeat-administration of autologous MSC-NTF cells and was supported by a grant from the California Institute for Regenerative Medicine (CIRM CLIN2-0989). BrainStorm completed under an investigational new drug application a Phase 2 open-label multicenter trial (NCT03799718) of autologous MSC-NTF cells in progressive multiple sclerosis (MS) and was supported by a grant from the National MS Society (NMSS).
For more information, visit the company's website atwww.brainstorm-cell.com.
Statements in this announcement other than historical data and information, including statements regarding future NurOwnmanufacturing and clinical development plans, constitute "forward-looking statements" and involve risks and uncertainties that could cause BrainStorm Cell Therapeutics Inc.'s actual results to differ materially from those stated or implied by such forward-looking statements. Terms and phrases such as "may," "should," "would," "could," "will," "expect,""likely," "believe," "plan," "estimate," "predict," "potential," and similar terms and phrases are intended to identify these forward-looking statements. The potential risks and uncertainties include, without limitation, BrainStorm's need to raise additional capital, BrainStorm's ability to continue as a going concern, the prospects for regulatory approval of BrainStorm's NurOwntreatment candidate, the initiation, completion, and success of BrainStorm's product development programs and research, regulatory and personnel issues, development of a global market for our services, the ability to secure and maintain research institutions to conduct our clinical trials, the ability to generate significant revenue, the ability of BrainStorm's NurOwntreatment candidate to achieve broad acceptance as a treatment option for ALS or other neurodegenerative diseases, BrainStorm's ability to manufacture, or to use third parties to manufacture, and commercialize the NurOwntreatment candidate, obtaining patents that provide meaningful protection, competition and market developments, BrainStorm's ability to protect our intellectual property from infringement by third parties, heath reform legislation, demand for our services, currency exchange rates and product liability claims and litigation; and other factors detailed in BrainStorm's annual report on Form 10-K and quarterly reports on Form 10-Q available athttp://www.sec.gov. These factors should be considered carefully, and readers should not place undue reliance on BrainStorm's forward-looking statements. The forward-looking statements contained in this press release are based on the beliefs, expectations and opinions of management as of the date of this press release. We do not assume any obligation to update forward-looking statements to reflect actual results or assumptions if circumstances or management's beliefs, expectations or opinions should change, unless otherwise required by law. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements.
Investor Relations:Eric GoldsteinLifeSci Advisors, LLCPhone: +1 (646) firstname.lastname@example.org
Media:Mariesa Kemble email@example.com
View original content:
SOURCE Brainstorm Cell Therapeutics Inc
- Irving Weissman Laboratory | Institute for Stem Cell ... - December 4th, 2021
- Nine Things To Know About Stem Cell Treatments - A Closer ... - December 4th, 2021
- Regenerative Medicine & Stem Cell Therapy Las Vegas ... - December 4th, 2021
- World AIDS Day: is a cure for HIV finally in sight? - Thomson Reuters Foundation - December 4th, 2021
- New genetic technology for gene expression analysis of cancer cells - News-Medical.net - December 4th, 2021
- Stem Cell Therapy Restores Insulin Production in Patients with Type 1 Diabetes - MD Magazine - December 4th, 2021
- It takes guts to make a heart - EurekAlert - December 4th, 2021
- Appia Bio Announces Appointment of Irving Weissman, MD, and Mark Exley, PhD, to Scientific Advisory Board - BioSpace - December 4th, 2021
- The Intramural Research Program at the Abu Dhabi Stem Cell Center (ADSCC) Signs a Letter of Intent to Collaborate with the Division of Intramural... - December 4th, 2021
- TScan Therapeutics to Host a Virtual Event to Discuss Highlights from the 63rd ASH Annual Meeting and Exposition - GlobeNewswire - December 4th, 2021
- Genomic Testing Cooperative to Present data at the American Society of Hematology Meeting on its Proprietary Machine Learning Approaches for RNA... - December 3rd, 2021
- Cell Culture Media Market is predicted to grow from US$ 2.6 Bn in 2020 to over US$ 5.6 Bn by 2031 - PRNewswire - December 3rd, 2021
- Appia Bio Announces Appointment of Irving Weissman, MD, and Mark Exley, PhD, to Scientific Advisory Board - PRNewswire - December 3rd, 2021
- Treatment Tricks Cancer Cells Into Changing Their Identity To Eliminate Them - Technology Networks - December 3rd, 2021
- Soumit K. Basu MD PhD is recognized by Continental Who's Who - The Wellsboro Gazette - December 3rd, 2021
- Report of Placebo-Controlled Clinical Trial Evaluating MultiStem Cell Therapy for Acute Respiratory Distress Syndrome Published in Intensive Care... - November 30th, 2021
- Restorative treatments for erectile dysfunction arent proven to work. Men pay thousands anyway. - The Philadelphia Inquirer - November 30th, 2021
- Talaris Therapeutics Announces Initiation of Phase 2 Clinical Trial of FCR001 in Individuals with a Severe Form of Scleroderma - Yahoo Finance - November 30th, 2021
- Letter to the editor | In support of Hakeem Jefferson and the Early Career Black Faculty Group - The Stanford Daily - November 30th, 2021
- Jasper Therapeutics: Advancing Cures With HSC Transplants And Safer Prior Conditioning - Seeking Alpha - November 30th, 2021
- Immunomic Therapeutics Announces Collaboration With iOncologi - BioSpace - November 28th, 2021
- How drugs are reviewed and approved in Canada - The Globe and Mail - November 27th, 2021
- JGC : Investment in two companies in the MSC regenerative medicine and digital therapeutics fields through CVC fund - marketscreener.com - November 27th, 2021
- Global Cell Therapy Manufacturing Market Report 2021, Featuring Key Players KBI Biopharma, Waisman Biomanufacturing, Merck and Thermo Fisher... - November 27th, 2021
- Digital twins for predictive oncology will be a paradigm shift for precision cancer care - Nature.com - November 27th, 2021
- From tummy tucks to facelifts: Pet plastic surgery is happening in Ohio - NewsNation Now - November 27th, 2021
- Susanna Park inducted as holder of Roth Endowed Chair for Discovery, Education and Patient Care - UC Davis Health - November 24th, 2021
- Global Cell Therapy Markets Report 2021-2030: Cell Therapy Markets According to Therapeutic Areas, Technologies, & Companies - PRNewswire - November 24th, 2021
- Research Developments in the Treatment of Advanced Kidney Cancer - liherald - November 24th, 2021
- The Expanding Role of Interferons in Myeloproliferative Neoplasms - Targeted Oncology - November 24th, 2021
- InGeneron Publishes Significant Support for the Existence of Naturally Pluripotent Stem Cells in All Organs in the Adult Body - Galveston County Daily... - November 24th, 2021
- UoH start-up ties up with GenepoweRx for personalizing medical procedures - United News of India - November 24th, 2021
- BioRestorative Therapies Enters into Letter of Intent with PRC Clinical - BioSpace - November 22nd, 2021
- FDA Action Alert: Takeda, Aadi and Fennec - BioSpace - November 22nd, 2021
- New MedHouse Location Opens in West Palm Beach, Powered by R3 Health: Popular Concierge Membership Social Wellness and Biohacking Club Welcomes New... - November 22nd, 2021
- Researchers use model of hypothalamus to implicate genes associated with sleep, BMI, puberty, and more - EurekAlert - November 21st, 2021
- Orchard Therapeutics Announces New England Journal of Medicine Publication of Interim Proof-of-concept Study Results of OTL-203 for Hurler Syndrome -... - November 21st, 2021
- Gene Therapy May Reverse Hurler Syndrome, a Rare and Severe Illness in Kids - HealthDay - November 18th, 2021
- Braeden Lichti - Investing in Precision Medicine to Yield New Treatments for Neurodegenerative Diseases - PRNewswire - November 18th, 2021
- Orchard Therapeutics Announces New England Journal of Medicine Publication of Interim ... - The Bakersfield Californian - November 18th, 2021
- Diabetes breakthrough: Revolutionary stem cell technique treated 'severe' disease in study - Daily Express - November 18th, 2021
- French biotech CellProthera welcomes three exceptional talents to its executive management team - Business Wire - November 18th, 2021
- FDA Approves Merck's KEYTRUDA (pembrolizumab) as Adjuvant Therapy for Certain Patients With Renal Cell Carcinoma (RCC) Following Surgery - Business... - November 18th, 2021
- BioBridge Global continues history of innovation with umbilical cord collection and processing under cGMP standards for further manufacture -... - November 18th, 2021
- PhD Studentship, Cartilage Regenerative Medicine job with UNIVERSITY OF SOUTHAMPTON | 271677 - Times Higher Education (THE) - November 16th, 2021
- Behind the FDA Approval: Belumosudil for Chronic Graft Versus Host Disease - Targeted Oncology - November 16th, 2021
- Dr. Nathan Newman Recognized as a Professional of the Year for 2021 by Strathmore's Who's Who Worldwide - PR.com - November 16th, 2021
- A second HIV patient may have been 'cured' of infection without stem cell treatment, in extremely rare case - CNN - November 16th, 2021
- miRNA-based therapeutics to treat Glioblastoma at Johns Hopkins Medical Institute in Baltimore - Open Access Government - November 16th, 2021
- New dates announced for global scientific conference recruited to Memphis by UT Health Science Center and Tennessee Institute of Regenerative Medicine... - November 13th, 2021
- Regenerative Medicine Market to reach US$ 25,959.5 Mn by end of 2028, Says Coherent Market Insights - PRNewswire - November 13th, 2021
- ASCO Reading Room | CAR T-Cell Therapy in Hematologic Malignancies | MedPage Today - MedPage Today - November 13th, 2021
- This Week at FDA: CDRH and Endologix leaks, OTC monograph reform, and more - Regulatory Focus - November 13th, 2021
- Always Ready: A military man's motto on service and cancer - Yale School of Medicine - November 13th, 2021
- 100 years after insulin treatment was invented, researchers hope to ditch needles once and for all - CBC.ca - November 13th, 2021
- These 5 Things Can Cause Your Hip to Collapse Eat This Not That - Eat This, Not That - November 13th, 2021
- Athersys Reports Updates on Timing for Japan ARDS and Stroke Programs From Healios KK - GuruFocus.com - November 13th, 2021
- Putting the move back in movement - Scope - Scope - November 11th, 2021
- Revolutionizing the way we treat lack of blood flow diseases by using stem cell therapy - InvestorIntel - November 11th, 2021
- Creative Medical Technology Holdings Announces Implementation of Reverse Stock Split in Preparation for Planned Uplisting to The Nasdaq Capital Market... - November 11th, 2021
- It takes a village (of cells) to heal the intestine - Baylor College of Medicine News - November 11th, 2021
- Fate Therapeutics Announces Abstract Highlighting FT538 and FT573 Programs Selected for Presentation at SITC 2021 Annual Meeting Press Conference -... - November 11th, 2021
- CAR T-cell therapy: Hear from a Canadian patient - CTV News - November 9th, 2021
- UM teams to research under-studied aspects of COVID-19 - UM Today - November 9th, 2021
- COVID Booster Eligibility: Who Can Get the Third Vaccine Dose Now? - NBC10 Boston - November 9th, 2021
- He cant cure his dad. But a scientists research may help everyone else. - The Indian Express - November 9th, 2021
- Hoth Therapeutics Inks API and Drug Product Contracts with WuXi STA to Advance Manufacturing of HT-KIT Cancer Therapeutic - Yahoo Finance - November 9th, 2021
- MS in Stem Cell Biology and Regenerative Medicine - November 7th, 2021
- Institute for Stem Cell & Regenerative Medicine ... - November 7th, 2021
- Stem-cell niche - Wikipedia - November 7th, 2021
- Stem Cell Network - November 7th, 2021
- This is such an important moment: how stem cell research ... - November 7th, 2021
- Experts gain insights into pathomechanisms of dilated cardiomyopathy - News-Medical.Net - November 7th, 2021
- Updates in Therapies of Relapsed and Refractory Follicular Lymphoma - Cancer Network - November 7th, 2021
- Totipotent Stem Cell - an overview | ScienceDirect Topics - November 7th, 2021
- Editas Medicine to Present Data Demonstrating Progress Towards Transformative Gene Editing Medicines for the Treatment of Hemoglobinopathies and... - November 5th, 2021
- Parkinson's gene therapy restores responses to dopamine-boosting drug in mouse models - FierceBiotech - November 5th, 2021
- Treatment Sequencing Could Change With Complementary Combinations and CAR T Options in B-ALL - OncLive - November 5th, 2021
- Shockwave therapy brings new healing opportunities for heart attack patients and hope for people with spinal cord injuries - WDRB - November 5th, 2021
- Clade Therapeutics Raises $87 Million Series A Financing to - GlobeNewswire - November 5th, 2021